U.S. body says gene therapy may be more cost effective for spinal muscular atrophy
By Caroline Humer and John Miller NEW YORK/ZURICH (Reuters) – Biogen Inc’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the...
Read More